Wednesday, July 8, 2026

pharma · SBRT · Covid19 · GRTX

Kailera Therapeutics

Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis.

Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
Status
Public
HQ
Waltham, Massachusetts, United States
Founded
2024
Employees
153
Programs
17
Drugs
7
Patents
23
Clinical program

Dextromethorphan HBr

Phase 1 · small molecule · Healthy

Dextromethorphan HBr for Healthy is a Phase 1 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).

← All Galera Therapeutics projects Phase 1 small molecule completed

Internal code GTI-4419-005

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Galera Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Healthy
Status
completed
Trials
1